GlassScriptPhysician profile
Kalyn Hoffman
NPI 1558998716
$3,681.40
in general payments reported to CMS, 2019-2025
24 companies · $2,158 in 2025
The $2,158 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $151 · 2022: $258 · 2023: $213 · 2024: $902 · 2025: $2,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,273.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $783.45 | 2022-2025 | |
| Genzyme Corporation | $470.95 | 2024-2025 | |
| Ucb, INC. | $270.41 | 2025 | Bimzelx |
| Janssen Biotech, INC. | $238.52 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Galderma Laboratories, L.P. | $236.02 | 2024-2025 | Nemluvio, Aklief |
| Incyte Corporation | $194.35 | 2023-2025 | Opzelura |
| Amgen INC. | $190.67 | 2024-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $164.01 | 2024-2025 | |
| Stemline Therapeutics INC. | $150.76 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $146.96 | 2022-2025 | Dupixent |
| Leo Pharma INC. | $145.89 | 2024-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $116.77 | 2023-2025 | Sotyktu |
| Almirall LLC | $97.41 | 2024-2025 | Klisyri, Seysara |
| Lilly USA, LLC | $78.56 | 2025 | Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $73.42 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.60 | 2023-2025 | Spevigo |
| Organon LLC | $43.20 | 2025 | Vtama |
| Biofrontera INC. | $36.86 | 2025 | |
| Blueprint Medicines Corporation | $36.13 | 2025 | Ayvakit |
| Pfizer INC. | $33.18 | 2024-2025 | |
| Botanix Sb INC | $28.06 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.82 | 2025 | Cabtreo, Jublia, Siliq |
| Dermavant Sciences, INC. | $24.80 | 2023 | Vtama |
| Strata Skin Sciences, INC. | $23.60 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kalyn Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.